Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy

Clin Infect Dis. 2004 Oct 1;39(7):1030-7. doi: 10.1086/423388. Epub 2004 Sep 1.

Abstract

Background: Technical limitations in the sensitivity of commercial genotyping methods may prevent clinicians from determining whether drug-resistant human immunodeficiency virus type 1 (HIV-1) is present in patients with low-level viremia. We performed ultrasensitive HIV-1 genotyping for patients with persistent plasma virus loads of 50-400 copies/mL to better define the prevalence of drug resistance and the most common resistance mutations during persistently detectable low-level viremia.

Methods: Genotyping of HIV-1 was performed with an ultrasensitive clonal genotyping method.

Results: We studied 21 patients who had persistent, detectable, low-level viremia for a median of 11 months. Nine (43%) of 21 patients had HIV-1 isolates with significant resistance mutations. The most common mutations were M184V, K65R, and M41L/T215Y.

Conclusions: The finding that clinically significant resistance mutations were present in some but not all patients with persistent viremia (range, 50-400 copies/mL) highlights the need to improve the sensitivity of current clinical assays for detection of drug resistance.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Anti-HIV Agents / therapeutic use
  • Antiretroviral Therapy, Highly Active*
  • Drug Resistance, Viral / genetics*
  • Female
  • Genotype
  • HIV Infections / virology*
  • HIV-1 / genetics*
  • Humans
  • Male
  • Middle Aged
  • Mutation
  • Viral Load
  • Viremia / virology*

Substances

  • Anti-HIV Agents